Shop Now Contact

In Vivo Star Anti-Mouse CD279 (PD1) / CD274 (PD-L1) Bispecific Antibody

Cat # Size Price Quantity
5136011 mg$1750
5136025 mg$5950
51360325 mg$17850

  Bulk/Custom

Product Details

Clone29F.1A12 / 10F.9G2
ApplicationFunctional assay, animal model study
Host SpeciesCHO cells
ReactivityMouse
FormatLiquid
Target NamePD1, PD-1, PDCD1, CD279, SLEB2
Product DescriptionIn Vivo Grade Recombinant Anti-mouse PD-1 / PD-L1 Bispecific Antibody
IsotypeMouse IgG2c LALAPG Kappa
Antibody TypeRecombinant
Regulatory StatusRUO
Purity>95% by reducing SDS-PAGE
Endotoxin< 1 EU per 1 mg of the protein by the LAL method.
Storage Conditions4ºC
GradeIn vivo
Recommended UsageThis product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
RRIDAB_3739411
Research AreasImmune Checkpoints, Activated T cells, Cancer Immunology, Tregs, Tfh cells, Activated B cells
See All FormatsClone 29F.1A12 / 10F.9G2

Background Information

CD279, also known as Programmed Cell Death Protein 1 (PD-1), is a crucial immune checkpoint receptor that regulates T cell activation and prevents autoimmunity. This transmembrane protein plays a pivotal role in maintaining immune homeostasis by delivering inhibitory signals that dampen excessive immune responses.

PD-1 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. It contains an extracellular immunoglobulin variable (IgV)-like domain, a transmembrane region, and an intracellular tail with two tyrosine-based signaling motifs: an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). When engaged, these motifs recruit phosphatases that inhibit T-cell receptor signaling, effectively suppressing T-cell activation, proliferation, and cytokine production.

PD-1 interacts with two primary ligands: PD-L1 (B7-H1/CD274) and PD-L2 (B7-DC/CD273). PD-L1 is widely expressed on various cell types, including tumor cells, antigen-presenting cells, and non-hematopoietic tissues, while PD-L2 expression is more restricted to antigen-presenting cells. These ligand-receptor interactions serve as critical brakes on immune responses. In cancer, tumor cells exploit the PD-1/PD-L1 pathway to evade immune surveillance. By upregulating PD-L1 expression, tumors effectively "turn off" infiltrating T-cells, preventing effective anti-tumor immunity. This mechanism contributes to tumor progression and immune escape across multiple cancer types.

The discovery of PD-1's role in cancer has revolutionized oncology through immune checkpoint inhibitors. Monoclonal antibodies targeting PD-1 (pembrolizumab, nivolumab) or PD-L1 (atezolizumab, durvalumab) block this inhibitory pathway, reinvigorating anti-tumor T-cell responses. These therapies have demonstrated remarkable success in treating melanoma, non-small cell lung cancer, renal cell carcinoma, and numerous other malignancies, fundamentally transforming cancer treatment paradigms and offering durable responses in previously untreatable cancers.

Data Sheets

In Vivo Star Anti-Mouse CD279 (PD1) / CD274 (PD-L1) Bispecific Antibody TDS

Related Products

In Vivo Star Anti-Mouse CD279 (PD1) / CD274 (PD-L1) Bispecific Antibody, Clone RMP1-14 / 10F.9G2

Anti-Mouse CD274 (PD-L1) Antibody, Clone 10F.9G2

Biotin Anti-Mouse CD274 (PD-L1) Antibody, Clone 10F.9G2

Anti-Human PD-L1 (Atezolizumab Biosimilar), Clone Atezolizuma

Anti-Human PD-L1 (Avelumab Biosimilar), Clone Avelumab

Anti-Human PD1 (Camrelizumab Biosimilar), Clone Camrelizumab

Anti-Human PD1 (Cemiplimab Biosimilar), Clone Cemiplimab

Anti-Human PD1 (Nivolumab Biosimilar), Clone Nivolumab

Anti-Human PD1 (Pembrolizumab Biosimilar), Clone Pembrolizumab

Anti-Human PD1 (Spartalizumab Biosimilar), Clone Spartalizumab

Frequently Asked Questions

What are In Vivo Star Biofunctional Antibodies?
In Vivo Star antibodies are premium-grade monoclonal antibodies purified and formulated specifically for use in animal studies. Each lot is manufactured under stringent quality controls to ensure the low endotoxin levels, high purity, and functional activity required for reliable in vivo results.
How are these antibodies different from standard research antibodies (e.g., for Western blot or flow cytometry)?
Standard research antibodies are optimized for in vitro detection assays and may contain preservatives, carrier proteins (like BSA), or higher endotoxin levels unsuitable for injection. In Vivo Star antibodies are formulated in injectable-grade, azide-free, low-endotoxin buffers and validated for functional bioactivity in living systems rather than just antigen binding.
What endotoxin and purity specifications do these antibodies meet?
All In Vivo Star antibodies are tested and certified to meet low-endotoxin thresholds (typically <1 EU/mg, lot-dependent) using the LAL (Limulus Amebocyte Lysate) assay, and are purified to ≥95% purity by SEC-HPLC or SDS-PAGE. Exact specifications are provided on the Certificate of Analysis (CoA) for each lot.
Are these antibodies azide-free and carrier-free?
All In Vivo Star antibodies are formulated without sodium azide and without carrier proteins such as BSA or gelatin, since both can interfere with animal physiology or immune readouts during in vivo studies.
Do you provide isotype controls?
Matched isotype control antibodies (same host species, isotype, and formulation) are available upon request for most clones to support proper experimental controls.
How should In Vivo Star antibodies be stored and handled?
Store at 4°C for short-term use and avoid repeated freeze-thaw cycles, which can reduce bioactivity; aliquoting is recommended for long-term storage per the product-specific storage instructions on the Certificate of Analysis. Always confirm storage conditions and expiration on the CoA that accompanies each lot, as these can vary slightly by antibody.

Have a product or application question? Consult our FAQs or contact us.